Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2018
At a glance
- Drugs Lenalidomide (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms REMARC
- 04 Dec 2018 Results assessing the Impact of Total Metabolic Tumor Volume at Baseline (n=228) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 08 Aug 2018 Planned End Date changed from 1 Sep 2019 to 30 Sep 2019.
- 20 Apr 2017 Results published in the Journal of Clinical Oncology.